A new experimental drug called JP-2266 significantly lowered blood sugar levels in people with type 2 diabetes over 12 weeks, reducing HbA1c by 0.94-0.97% compared to placebo. According to Gram Research analysis of this 156-person randomized controlled trial, the medication also helped participants lose 2-2.1 kg and lower blood pressure without serious side effects, though the drug isn’t yet approved for use and larger studies are needed to confirm these results.
Researchers tested a new medication called JP-2266 on 156 people with type 2 diabetes who weren’t controlling their blood sugar through diet and exercise alone. In a 12-week study, people taking JP-2266 saw their blood sugar levels drop significantly more than those taking a fake pill. The drug also helped people lose weight and lower their blood pressure without causing serious side effects. According to Gram Research analysis, these results suggest JP-2266 could become a helpful new treatment option for people struggling to manage their diabetes.
Key Statistics
A 2026 randomized controlled trial of 156 people found that JP-2266, a new dual SGLT1/SGLT2 inhibitor, reduced HbA1c by 0.94% at the 5 mg dose and 0.97% at the 10 mg dose compared to placebo over 12 weeks (P<0.0001).
In the same 156-person Phase 2 trial, JP-2266 reduced fasting blood glucose by 36-39 mg/dL and postprandial glucose by 62-67 mg/dL, with participants also losing 2-2.1 kg of body weight over 12 weeks.
The 2026 JP-2266 trial showed adverse event rates were similar between the medication and placebo groups, suggesting the drug was well-tolerated in the 12-week study period.
The Quick Take
- What they studied: Whether a new medication called JP-2266 could help people with type 2 diabetes control their blood sugar better than a placebo (fake pill)
- Who participated: 156 adults with type 2 diabetes whose blood sugar wasn’t well controlled by diet and exercise alone. Participants were randomly divided into three groups: one taking 5 mg of JP-2266, one taking 10 mg of JP-2266, and one taking a placebo
- Key finding: Both doses of JP-2266 significantly lowered blood sugar levels. The 5 mg dose reduced HbA1c (a measure of average blood sugar) by 0.94%, and the 10 mg dose reduced it by 0.97%, compared to placebo. These improvements were statistically significant (P<0.0001), meaning they weren’t due to chance
- What it means for you: If you have type 2 diabetes that diet and exercise alone aren’t controlling, JP-2266 might be a new medication option worth discussing with your doctor. However, this is early-stage research, and the drug isn’t yet approved for use. More testing is needed before it becomes available
The Research Details
This was a randomized controlled trial, which is considered one of the strongest types of medical research. Researchers randomly assigned 156 people with type 2 diabetes into three groups: one receiving 5 mg of JP-2266 daily, one receiving 10 mg daily, and one receiving a placebo (fake pill). Neither the participants nor the researchers knew who was getting the real drug versus the placebo—this is called “double-blind” and helps prevent bias. The study lasted 12 weeks, and researchers measured blood sugar levels and other health markers at the beginning and end.
JP-2266 is a “dual inhibitor,” meaning it works in two ways to help control blood sugar. It blocks two different proteins in the kidneys that normally allow sugar to be reabsorbed into the bloodstream. By blocking these proteins, the drug helps the body get rid of excess sugar through urine, which lowers blood sugar levels.
This was a Phase 2 trial, which is an early stage of drug testing. Phase 2 studies focus on whether a drug works and is safe in a relatively small group of people. If successful, Phase 2 results lead to larger Phase 3 trials before a drug can be approved by regulators like the FDA.
Randomized controlled trials are the gold standard for testing whether medications actually work because they eliminate many sources of bias. By randomly assigning people to groups and using a placebo, researchers can be confident that any differences between groups are due to the medication, not other factors. The double-blind design is especially important because it prevents both patients and doctors from unconsciously influencing results based on their expectations
This study has several strengths: it used a proper control group (placebo), was double-blind, randomly assigned participants, and measured multiple relevant outcomes (blood sugar, weight, blood pressure). The sample size of 156 is reasonable for a Phase 2 trial. However, the study only lasted 12 weeks, so we don’t know if the benefits continue long-term or if side effects might appear over months or years. The study also only included people whose diabetes wasn’t controlled by lifestyle changes, so results may not apply to everyone with type 2 diabetes
What the Results Show
JP-2266 significantly improved blood sugar control compared to placebo. The 5 mg dose reduced HbA1c by 0.94% and the 10 mg dose by 0.97%, both with very strong statistical significance (P<0.0001). To put this in perspective, an HbA1c reduction of about 1% is considered clinically meaningful and can reduce the risk of diabetes complications.
The drug also lowered fasting blood sugar (the level when you haven’t eaten for several hours). The 5 mg dose reduced fasting glucose by 36.22 mg/dL, and the 10 mg dose by 39.38 mg/dL. Additionally, JP-2266 reduced blood sugar spikes after meals (postprandial glucose), with reductions of 62.30 mg/dL at the 5 mg dose and 66.89 mg/dL at the 10 mg dose.
Beyond blood sugar control, participants taking JP-2266 lost weight—about 2 to 2.1 kg (roughly 4.4 to 4.6 pounds) over the 12-week period. The 10 mg dose also lowered systolic blood pressure by 3.6 mm Hg. These additional benefits are important because people with type 2 diabetes often struggle with weight and high blood pressure, which increase their risk of heart disease.
The study measured insulin resistance and pancreatic beta-cell function (the cells that produce insulin) using a mathematical model called HOMA. Both improved with JP-2266 treatment, suggesting the drug helps the body use insulin more effectively and may help preserve the pancreas’s ability to produce insulin. This is encouraging because type 2 diabetes involves both insulin resistance and declining beta-cell function over time
JP-2266 is a dual SGLT1/SGLT2 inhibitor, a newer class of diabetes drugs. SGLT2 inhibitors alone are already approved and used to treat type 2 diabetes. This study suggests that adding SGLT1 inhibition might provide additional benefits. The blood sugar reductions seen with JP-2266 are comparable to or better than some existing diabetes medications, though direct head-to-head comparisons would be needed to know for certain
The study only lasted 12 weeks, so we don’t know if benefits continue beyond that timeframe or if new side effects might emerge with longer use. The sample size of 156 is relatively small for a medication study—larger Phase 3 trials will be needed to confirm these results and identify rare side effects. The study only included people whose diabetes wasn’t controlled by lifestyle changes, so results may not apply to people with milder diabetes or those already taking other medications. Additionally, the study didn’t compare JP-2266 to existing diabetes medications, only to placebo, so we can’t say whether it’s better or worse than current treatment options
The Bottom Line
JP-2266 shows promise as a new treatment for type 2 diabetes based on this Phase 2 trial, but it’s not yet approved for use. If you have type 2 diabetes that diet and exercise aren’t controlling, continue working with your doctor on current treatment options. In the future, if JP-2266 becomes available, it may be worth discussing with your healthcare provider as a potential option. The evidence from this study is moderately strong for a Phase 2 trial, but larger, longer studies are needed before making definitive recommendations
This research is most relevant to people with type 2 diabetes whose blood sugar isn’t well controlled by lifestyle changes alone. It may also interest people who have tried other diabetes medications and want to know about new options in development. Healthcare providers treating type 2 diabetes should be aware of this emerging medication. People with type 1 diabetes or those whose diabetes is well-controlled with current treatments don’t need to make changes based on this research
In this 12-week study, blood sugar improvements appeared relatively quickly, with significant reductions by the end of the trial. Weight loss was modest (about 2 kg), so realistic expectations would be gradual weight loss over several months if the drug becomes available. However, this is early-stage research, and it typically takes 3-5 years or more for a drug to move from Phase 2 trials through Phase 3 testing and regulatory approval
Frequently Asked Questions
How does JP-2266 work to lower blood sugar?
JP-2266 blocks two proteins in the kidneys that normally reabsorb sugar from urine back into the bloodstream. By blocking these proteins, the drug allows excess sugar to be eliminated through urine, directly lowering blood glucose levels.
Is JP-2266 available to take right now?
No, JP-2266 is not yet approved or available. This Phase 2 trial is early-stage testing. The drug must complete Phase 3 trials and receive regulatory approval before it can be prescribed, which typically takes several more years.
How much weight did people lose taking JP-2266?
In the 12-week study, participants taking JP-2266 lost 2 to 2.1 kg (about 4.4 to 4.6 pounds). This modest weight loss occurred alongside significant blood sugar improvements, which is beneficial for people with type 2 diabetes.
What side effects did people experience with JP-2266?
The study reported that adverse event rates were similar between JP-2266 and placebo groups, suggesting the drug was well-tolerated. However, the 12-week timeframe is relatively short, and larger, longer studies are needed to identify potential long-term side effects.
Is JP-2266 better than existing diabetes medications?
This study compared JP-2266 only to placebo, not to existing diabetes drugs, so direct comparisons aren’t available yet. The blood sugar reductions appear promising, but larger trials comparing it to current medications would be needed to determine if it’s better or worse.
Want to Apply This Research?
- Track fasting blood glucose readings (blood sugar measured before eating) weekly and HbA1c levels every 3 months if you’re monitoring diabetes. Record readings in the app to visualize trends and share with your healthcare provider
- While waiting for new medications, use the app to log meals and monitor how different foods affect your blood sugar. Set reminders for consistent meal times and physical activity, which remain the foundation of diabetes management regardless of medication
- Create a dashboard showing your blood sugar trends over time, weight changes, and blood pressure readings. Set monthly goals for gradual improvements and track progress. Share reports with your doctor to guide treatment decisions
This article summarizes research findings from a Phase 2 clinical trial and is for educational purposes only. JP-2266 is not yet approved by the FDA or other regulatory agencies and is not available for use. Do not make changes to your diabetes treatment based on this research. Always consult with your healthcare provider before starting, stopping, or changing any diabetes medication or treatment plan. If you have type 2 diabetes, work with your doctor to develop a personalized treatment strategy based on your individual health needs and current approved medications.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.